Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistical analysis plan considerations for autologous cell and cell-based gene therapy clinical trials.

Journal of biopharmaceutical statistics·2026
Same author

Overview of dose-finding designs and trials in cell and gene therapies.

Journal of biopharmaceutical statistics·2026
Same author

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same author

Testing rates and outcomes in <i>Clostridioides difficile</i> infection between REM (racially and ethnically minoritized) and non-REM patients.

Infection control and hospital epidemiology·2026
Same author

Exploiting vitamin C as a prooxidant to activate ROS-responsive prodrugs for potent and selective tumor killing.

Redox biology·2026
Same author

Pivotal trial design considerations for new and next generation cell and gene therapies.

Journal of biopharmaceutical statistics·2026

Related Experiment Video

Updated: Jun 27, 2025

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

837

Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical

Daniel Li1, Zhenzhen Xu2, Shihua Wen3

  • 1Bristol Myers Squibb, Seattle, WA, USA. daniel.li1@bms.com.

Therapeutic Innovation & Regulatory Science
|May 4, 2024
PubMed
Summary

Chimeric antigen receptor (CAR) T-cell therapy shows promise for blood cancers. This review addresses key statistical challenges in CAR T-cell clinical development, including dose finding and data analysis for approved therapies.

Keywords:
CAR T-cellCell and gene therapyDose-findingEstimandLong-term follow-upReal-world evidence

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

498
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

Related Experiment Videos

Last Updated: Jun 27, 2025

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

837
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

498
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Chimeric antigen receptor (CAR) T-cell therapy involves genetically modifying a patient's T cells to target specific antigens.
  • Autologous CAR T cells have demonstrated significant antitumor activity, leading to six FDA approvals for hematological malignancies since 2017.

Purpose of the Study:

  • To summarize and address the statistical challenges encountered in the clinical development of CAR T-cell therapies.
  • To provide insights based on the development of six approved CAR T-cell products.

Main Methods:

  • Review of statistical considerations for CAR T-cell therapies.
  • Analysis of challenges based on approved CAR T-cell products.

Main Results:

  • Identified statistical hurdles include dose-finding strategies, the estimand framework, real-world data utilization, safety data analysis, and long-term follow-up.
  • This paper is the first to systematically summarize these statistical challenges.

Conclusions:

  • Addressing these statistical challenges is crucial for the continued advancement of CAR T-cell therapy development.
  • Standardizing statistical approaches will enhance the reliability and efficiency of clinical trials for CAR T-cell products.